跳转至内容
Merck

A2795

Sigma-Aldrich

N-乙酰-d-半乳糖胺

≥98% (HPLC)

别名:

2-乙酰氨基-2-脱氧-D-半乳糖, D-GalNAc, N-乙酰半乳糖胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H15NO6
CAS号:
分子量:
221.21
Beilstein:
2331340
EC號碼:
MDL號碼:
分類程式碼代碼:
12352201
PubChem物質ID:
NACRES:
NA.25

品質等級

化驗

≥98% (HPLC)

形狀

powder

技術

HPLC: suitable

顏色

white

mp

160 °C

溶解度

water: 50 mg/mL, clear, colorless

儲存溫度

2-8°C

SMILES 字串

CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O

InChI

1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8?/m1/s1

InChI 密鑰

OVRNDRQMDRJTHS-KEWYIRBNSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

N-乙酰-D-半乳糖胺 (GalNAc) 是一种氨基糖,是许多 O-连接和N-连接聚糖结构的组成部分。作为尿苷二磷酸 (UDP)-GalNAc,GalNAc是许多丝氨酸和苏氨酸残基蛋白质糖基化的初始O连接糖。

應用

N-乙酰-D-半乳糖胺已用于:
  • 用作双花扁豆凝集素 (DBA) 半抗原糖,用于凝集素珠结合测定
  • 通过凝集素印迹抑制评估凝集素结合的特异性
  • 免疫组织化学预吸附紫藤凝集素

N-乙酰-D-半乳糖胺(GalNAc)是一种氨基糖,是许多O-连接和N连接聚糖结构的组分。 作为UDP-GalNAc,GalNAc是许多蛋白质糖基化丝氨酸和苏氨酸残基的起始O-连接糖。

其他說明

为了全面了解我们针对客户研究提供的各种单糖产品,建议您访问我们的碳水化合物分类页面。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

P Van den Steen et al.
Critical reviews in biochemistry and molecular biology, 33(3), 151-208 (1998-07-23)
The biosynthesis, structures, and functions of O-glycosylation, as a complex posttranslational event, is reviewed and compared for the various types of O-glycans. Mucin-type O-glycosylation is initiated by tissue-specific addition of a GalNAc-residue to a serine or a threonine of the
Sian F Irvine et al.
International journal of molecular sciences, 19(4) (2018-04-13)
Perineuronal nets (PNNs) are extracellular matrix structures surrounding neuronal sub-populations throughout the central nervous system, regulating plasticity. Enzymatically removing PNNs successfully enhances plasticity and thus functional recovery, particularly in spinal cord injury models. While PNNs within various brain regions are
Yuki Kuramoto et al.
Journal of molecular and cellular cardiology, 121, 256-265 (2018-07-27)
Fabry disease is an X-linked disease caused by mutations in α-galactosidase A (GLA); these mutations result in the accumulation of its substrates, mainly globotriaosylceramide (Gb3). The accumulation of glycosphingolipids induces pathogenic changes in various organs, including the heart, and Fabry
Malte Lenders et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 32(12), 2090-2097 (2016-09-30)
Renal and cardiac involvement is responsible for substantial morbidity and mortality in Fabry disease (FD). We analysed the incidence of FD-related renal, cardiac and neurologic end points in patients with FD on long-term enzyme replacement therapy (ERT). A retrospective analysis
David J Gill et al.
Trends in cell biology, 21(3), 149-158 (2010-12-15)
O-GalNAc glycosylation of proteins confers essential structural, protective and signaling roles in eumetazoans. Addition of O-glycans onto proteins is an extremely complex process that regulates both sites of attachment and the types of oligosaccharides added. Twenty distinct polypeptide GalNAc-transferases (GalNAc-Ts)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门